AU2937199A - Method for diagnosing epilepsy and related disorders, and kit therefor - Google Patents

Method for diagnosing epilepsy and related disorders, and kit therefor

Info

Publication number
AU2937199A
AU2937199A AU29371/99A AU2937199A AU2937199A AU 2937199 A AU2937199 A AU 2937199A AU 29371/99 A AU29371/99 A AU 29371/99A AU 2937199 A AU2937199 A AU 2937199A AU 2937199 A AU2937199 A AU 2937199A
Authority
AU
Australia
Prior art keywords
related disorders
kit therefor
diagnosing epilepsy
epilepsy
diagnosing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU29371/99A
Inventor
Albert De La Chapelle
Mikko Jarvinen
Anna-Elina Lehesjoki
Ari Rinne
Riitta Rinne
Pekka Saukko
Kimmo Virtaneva
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aboatech Ltd
Original Assignee
Aboatech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aboatech Ltd filed Critical Aboatech Ltd
Publication of AU2937199A publication Critical patent/AU2937199A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96466—Cysteine endopeptidases (3.4.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2857—Seizure disorders; Epilepsy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU29371/99A 1998-03-23 1999-03-23 Method for diagnosing epilepsy and related disorders, and kit therefor Abandoned AU2937199A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI980647A FI980647A0 (en) 1998-03-23 1998-03-23 For the purposes of diagnostic diagnostics, for the diagnosis and differential diagnosis
FI980647 1998-03-23
PCT/FI1999/000228 WO1999049317A1 (en) 1998-03-23 1999-03-23 Method for diagnosing epilepsy and related disorders, and kit therefor

Publications (1)

Publication Number Publication Date
AU2937199A true AU2937199A (en) 1999-10-18

Family

ID=8551350

Family Applications (1)

Application Number Title Priority Date Filing Date
AU29371/99A Abandoned AU2937199A (en) 1998-03-23 1999-03-23 Method for diagnosing epilepsy and related disorders, and kit therefor

Country Status (3)

Country Link
AU (1) AU2937199A (en)
FI (1) FI980647A0 (en)
WO (1) WO1999049317A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112379093A (en) * 2020-10-22 2021-02-19 上海良润生物医药科技有限公司 Application of CST-Cathepsin compound as tumor diagnosis marker

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0922553D0 (en) * 2009-12-23 2010-02-10 Fusion Antibodies Ltd Prognostic marker
EP2766734A1 (en) * 2011-10-14 2014-08-20 Pronota NV Procathepsin l and cathepsin l as biomarkers for ischemia
WO2015042326A2 (en) * 2013-09-18 2015-03-26 University Of Notre Dame Du Lac Methods for detection and treatment of neurodegenerative diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992019756A1 (en) * 1991-05-02 1992-11-12 Idemitsu Kosan Company Limited Monoclonal antibody specific for cathepsin l, hybridoma which produces the same, and method for using the same
US5686269A (en) * 1994-07-28 1997-11-11 The Mclean Hospital Corporation Method of diagnosing Alzheimer's disease by detecting the level of cathepsin D in cerebrospinal fluid
US6432635B1 (en) * 1996-03-21 2002-08-13 Helsinki University Licensing Ltd. Oy Cystatin B mutants

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112379093A (en) * 2020-10-22 2021-02-19 上海良润生物医药科技有限公司 Application of CST-Cathepsin compound as tumor diagnosis marker

Also Published As

Publication number Publication date
WO1999049317A1 (en) 1999-09-30
FI980647A0 (en) 1998-03-23

Similar Documents

Publication Publication Date Title
AUPO616697A0 (en) Method for diagnosing psychiatric disorders
AU2869799A (en) Diagnostic method for analyzing emboli
AU2001243273A1 (en) System and method for diagnosing pathologic heart conditions
AU8573098A (en) Super progressive jackpot method
AU9104798A (en) Methods for selecting, developing and improving diagnostic tests for pregnancy-related conditions
IL176601A0 (en) Method for diagnosing and improving vision
AU3117799A (en) Method of identifying, diagnosing and treating synuclein positive neurodegenerative disorders
AU2002950878A0 (en) Method for diagnosing disorders
AUPP156698A0 (en) New method for hydrogen passivation
AU5064499A (en) Method for determining hemoglobins
AU6465798A (en) Diagnosing neurologic disorders
AU1117100A (en) Methods for assessing complement activation
AU3590199A (en) Method for diagnosing a vascular condition
AU9565698A (en) System and method for diagnosing vision disorders
AU7834198A (en) Face-gear forging method
AU3005595A (en) Method, reagents and kit for diagnosis and targeted screening for retinoblastoma
AU6105199A (en) Diagnostic method
AU8346498A (en) Method for diagnosing alzheimer disease
AU2937199A (en) Method for diagnosing epilepsy and related disorders, and kit therefor
AU2314099A (en) Secure exam method
AU4031499A (en) Method for producing polyurethanes
AU1988000A (en) Nmr spectroscopy method
AUPP612798A0 (en) Diagnostic method
AU2813797A (en) Method for diagnosing cancer
AU1833000A (en) Method for diagnosing neoplasia

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase